Filtered By:
Drug: Atenolol

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 41 results found since Jan 2013.

Systolic Blood Pressure Control and Mortality After Stroke in Hypertensive Patients Clinical Sciences
Conclusions— Lower achieved SBP (<144 mm Hg) is associated with a significantly increased risk of cardiovascular and all-cause mortality after initial stroke in hypertensive patients during short-term follow-up. Further study is required to determine ideal SBP goals after stroke. Clinical Trial Registration— URL: http://clinicaltrials.gov/. Unique identifier: NCT00338260.
Source: Stroke - July 27, 2015 Category: Neurology Authors: Okin, P. M., Kjeldsen, S. E., Devereux, R. B. Tags: Cerebrovascular disease/stroke, Epidemiology Clinical Sciences Source Type: research

Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy
Conclusion: Abnormal PTFV1, a marker of left atrial abnormality, was strongly associated with incident stroke in hypertensive patients, independent of in-treatment SBP and other predictors of incident stroke. This association, in the absence of detectable atrial fibrillation, suggests that an underlying atrial cardiopathy may cause left atrial thrombus formation and a subsequent stroke without intervening clinically recognized atrial fibrillation.
Source: Journal of Hypertension - August 5, 2016 Category: Cardiology Tags: ORIGINAL PAPERS: Heart Source Type: research

Perioperative Metoprolol and Risk of Stroke after Noncardiac Surgery
Background: Numerous risk factors have been identified for perioperative stroke, but there are conflicting data regarding the role of β adrenergic receptor blockade in general and metoprolol in particular. Methods: The authors retrospectively screened 57,218 consecutive patients for radiologic evidence of stroke within 30 days after noncardiac procedures at a tertiary care university hospital. Incidence of perioperative stroke within 30 days of surgery and associated risk factors were assessed. Patients taking either metoprolol or atenolol were matched based on a number of risk factors for stroke. Parsimonious logistic re...
Source: Anesthesiology - November 19, 2013 Category: Anesthesiology Tags: Perioperative Medicine Source Type: research

Beta-blockers for preventing stroke recurrence.
CONCLUSIONS: To date, no available evidence supports the routine use of beta-blockers for secondary prevention after stroke or TIA. More studies with larger samples are needed. PMID: 25317988 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - October 15, 2014 Category: Journals (General) Authors: De Lima LG, Saconato H, Atallah AN, da Silva EM Tags: Cochrane Database Syst Rev Source Type: research

S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats.
In conclusion, the present study demonstrates that post-treatment of S-ORC alleviates BBB dysfunction by regulating tight junction proteins (TJPs), upregulating P-glycoprotein function, and protects against ischemic stroke as results. PMID: 28760594 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - July 28, 2017 Category: Drugs & Pharmacology Authors: Huang L, Shang E, Fan W, Li X, Li B, He S, Fu Y, Zhang Y, Li Y, Fang W Tags: Eur J Pharm Sci Source Type: research

A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial
Lancet Glob Health. 2023 Oct;11(10):e1619-e1628. doi: 10.1016/S2214-109X(23)00347-9.ABSTRACTBACKGROUND: A cardiovascular polypill containing generic drugs might facilitate sustained implementation of and adherence to evidence-based treatments, especially in resource-limited settings. However, the impact of a cardiovascular polypill in mitigating atherosclerotic risk among stroke survivors has not been assessed. We aimed to compare a polypill regimen with usual care on carotid intima-media thickness (CIMT) regression after ischaemic stroke.METHODS: In SMAART, a phase 2 parallel, open-label, assessor-masked, randomised clini...
Source: Atherosclerosis - September 21, 2023 Category: Cardiology Authors: Fred Stephen Sarfo Jenifer Voeks Sheila Adamu Benedict Apaw Agyei Manolo Agbenorku Nyantakyi Adu-Darko Mercy Adomah Oteng Vida Obese Rexford Adu Gyamfi Nathaniel Adusei Mensah Raelle Tagge Michael Ampofo Samuel Amoabeng Kontoh Samuel Blay Nguah Bruce Ovbi Source Type: research

Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Authors: Mancusi C, Gerdts E, de Simone G, Midtbø H, Lønnebakken MT, Boman K, Wachtell K, Dahlöf B, Devereux RB Abstract We tested the prognostic impact of a marker of arterial stiffness, pulse pressure/stroke volume index (PP/SVi) in patients with hypertension and left ventricular (LV) hypertrophy. We used data from 866 patients randomized to losartan or atenolol-based antihypertensive treatment, over a median of 4.8 years, in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. The association of PP/SVi with outcomes was tested in Cox regression analyses and reported as hazard ratio (...
Source: Blood Pressure - October 7, 2016 Category: Hematology Tags: Blood Press Source Type: research

ASCOT: Amlodipine Cuts Stroke, Not Dementia Over Decades ASCOT: Amlodipine Cuts Stroke, Not Dementia Over Decades
Long-term follow up of the ASCOT trial comparing amlodipine- vs atenolol-based antihypertensive regimens shows reductions in stroke, but not dementia, with amlodipine over time.Medscape Medical News
Source: Medscape Cardiology Headlines - June 17, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Selective β1-Antagonism with Bisoprolol Is Associated with Fewer Postoperative Strokes than Atenolol or Metoprolol: A Single-center Cohort Study of 44,092 Consecutive Patients
Conclusions: The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol. These findings warrant confirmation in a pragmatic randomized trial.
Source: Anesthesiology - September 17, 2013 Category: Anesthesiology Tags: Perioperative Medicine Source Type: research

Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis
Conclusions In the young, both atenolol and nonatenolol β-blockers are effective in reducing cardiovascular end points for hypertension without compelling indications. Atenolol is associated with increased stroke in the elderly but whether this extends to nonatenolol β-blockers remains uncertain.
Source: Canadian Journal of Cardiology - November 1, 2014 Category: Cardiology Source Type: research

The Role of Beta-Blockers in the Treatment of Hypertension.
CONCLUSIONS AND RELEVANCE: Primary/essential hypertension in younger/middle-age is underpinned by high sympathetic nerve activity. In this age-group high resting heart rates and high plasma norepinephrine levels (independent of blood pressure) are linked to premature cardiovascular events and death. Thus, anti-hypertensive agents that increase sympathetic nerve activity ie diuretics, dihydropyridine calcium blockers, and ARBs, are inappropriate first-line choices in this younger age-group. Beta-blockers perform well vs randomised placebo and other antihypertensive agents regarding reduced risk of death/stroke/myocardial in...
Source: Advances in Experimental Medicine and Biology - December 14, 2016 Category: Research Tags: Adv Exp Med Biol Source Type: research

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study Clinical Trial
In the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, 4.8 years’ losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke. However, there was no difference in myocardial infarction (MI), possibly related to greater reduction in myocardial oxygen demand by atenolol-based treatment. Myocardial oxygen demand was assessed indirectly by the left ventricular massxwall stressxheart rate (triple product) in 905 LIFE participants. The triple product was included as time-varying covariate...
Source: Hypertension - October 7, 2015 Category: Cardiology Authors: Devereux, R. B., Bang, C. N., Roman, M. J., Palmieri, V., Boman, K., Gerdts, E., Nieminen, M. S., Papademetriou, V., Wachtell, K., Hille, D. A., Dahlof, B. Tags: Hypertrophy, Other etiology Clinical Trial Source Type: research

Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis
ConclusionsIn hypertensive subjects with excess weight, diuretics are more effective for preventing HF and stroke than CCB and ACEI, respectively. CCB are a good first-line choice for prevention of cardiovascular disease, except HF.
Source: American Journal of Cardiovascular Drugs - January 2, 2020 Category: Cardiology Source Type: research

Different β-Blockers and Initiation Time in Patients Undergoing Noncardiac Surgery: A Meta-analysis.
Abstract : The effects of differences among β-blockers and initiation times in patients undergoing noncardiac surgery (NCS) remain unknown. On June 1, 2012, the authors searched PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials to identify all trials of perioperative β-blockers in patients undergoing NCS published between January 1960 and June 2012. The authors included only randomized, double-blind and placebo-controlled trials of perioperatively administered β-blockers (ie, during the pre-, intra- and/or postoperative period) in patients with at least 1 risk factor for coronary ar...
Source: The American Journal of the Medical Sciences - April 12, 2013 Category: Journals (General) Authors: Dai N, Xu D, Zhang J, Wei Y, Li W, Fan B, Xu Y Tags: Am J Med Sci Source Type: research

A review of the use of Angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
CONCLUSIONS: Data supporting the use of ARBs for reducing cardiovascular events in patients with essential hypertension without compelling indications are limited and inconclusive. More studies are needed before ARBs can be routinely recommended as first-line therapy for hypertension management in patients without other compelling indications. PMID: 23585649 [PubMed - in process]
Source: The Annals of Pharmacotherapy - May 1, 2013 Category: Drugs & Pharmacology Authors: Zaiken K, Hudd TR, Cheng JW Tags: Ann Pharmacother Source Type: research